Johnson & Johnson (NYSE:JNJ) Shares Bought by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.5% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 201,581 shares of the company's stock after purchasing an additional 6,828 shares during the quarter. Johnson Investment Counsel Inc.'s holdings in Johnson & Johnson were worth $33,430,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Community Bank N.A. lifted its position in Johnson & Johnson by 4.0% in the first quarter. Community Bank N.A. now owns 47,656 shares of the company's stock valued at $7,903,000 after purchasing an additional 1,835 shares during the last quarter. Kiley Juergens Wealth Management LLC lifted its position in Johnson & Johnson by 2.5% in the first quarter. Kiley Juergens Wealth Management LLC now owns 17,909 shares of the company's stock valued at $2,970,000 after purchasing an additional 435 shares during the last quarter. State of Alaska Department of Revenue lifted its position in Johnson & Johnson by 14.5% in the first quarter. State of Alaska Department of Revenue now owns 352,378 shares of the company's stock valued at $58,437,000 after purchasing an additional 44,600 shares during the last quarter. CWA Asset Management Group LLC lifted its position in Johnson & Johnson by 2.6% in the first quarter. CWA Asset Management Group LLC now owns 123,552 shares of the company's stock valued at $20,490,000 after purchasing an additional 3,074 shares during the last quarter. Finally, Analyst IMS Investment Management Services Ltd. lifted its position in Johnson & Johnson by 43.0% in the first quarter. Analyst IMS Investment Management Services Ltd. now owns 10,380 shares of the company's stock valued at $1,722,000 after purchasing an additional 3,121 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Morgan Stanley upped their price target on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 16th. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Raymond James Financial cut their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Finally, The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Stock Down 0.6%

NYSE JNJ traded down $0.92 on Friday, reaching $149.81. 22,591,152 shares of the stock traded hands, compared to its average volume of 8,022,556. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The company has a fifty day moving average price of $154.07 and a 200-day moving average price of $153.63. The company has a market cap of $360.44 billion, a price-to-earnings ratio of 16.66, a PEG ratio of 2.28 and a beta of 0.42. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.47%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.